$735 Million is the total value of Tekla Capital Management LLC's 60 reported holdings in Q2 2013. The portfolio turnover from Q1 2013 to Q2 2013 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GILD | New | Gilead Sciences, Inc. | $77,056,000 | – | 1,504,712 | +100.0% | 10.48% | – |
| REGN | New | Regeneron Pharmaceuticals, Inc. | $62,912,000 | – | 279,759 | +100.0% | 8.56% | – |
| CELG | New | Celgene Corporation | $59,629,000 | – | 510,046 | +100.0% | 8.11% | – |
| BIIB | New | Biogen Idec, Inc. | $41,315,000 | – | 191,983 | +100.0% | 5.62% | – |
| VRTX | New | Vertex Pharmaceuticals, Inc. | $36,274,000 | – | 454,164 | +100.0% | 4.93% | – |
| ALXN | New | Alexion Pharmaceuticals, Inc. | $34,251,000 | – | 371,329 | +100.0% | 4.66% | – |
| PBYI | New | Puma Biotechnology, Inc. | $31,583,000 | – | 711,800 | +100.0% | 4.30% | – |
| PRGO | New | Perrigo Company | $24,515,000 | – | 202,607 | +100.0% | 3.33% | – |
| ONXX | New | Onyx Pharmaceuticals, Inc. | $22,040,000 | – | 253,856 | +100.0% | 3.00% | – |
| AMGN | New | Amgen, Inc. | $19,746,000 | – | 200,143 | +100.0% | 2.68% | – |
| WCRX | New | Warner Chilcott plcshares a | $15,562,000 | – | 782,797 | +100.0% | 2.12% | – |
| MYL | New | Mylan, Inc. | $15,149,000 | – | 488,209 | +100.0% | 2.06% | – |
| SHPG | New | Shire plcsponsored adr | $14,661,000 | – | 154,153 | +100.0% | 1.99% | – |
| MRK | New | Merck & Co., Inc. | $13,778,000 | – | 296,620 | +100.0% | 1.87% | – |
| CBST | New | Cubist Pharmaceuticals, Inc. | $12,846,000 | – | 265,972 | +100.0% | 1.75% | – |
| AKRXQ | New | Akorn, Inc. | $12,651,000 | – | 935,758 | +100.0% | 1.72% | – |
| AET | New | Aetna, Inc. | $12,533,000 | – | 197,241 | +100.0% | 1.70% | – |
| VSTM | New | Verastem, Inc. | $12,283,000 | – | 884,920 | +100.0% | 1.67% | – |
| TEVA | New | Teva Pharmaceutical Industries Ltd.adr | $12,210,000 | – | 311,476 | +100.0% | 1.66% | – |
| ACT | New | Actavis, Inc. | $11,549,000 | – | 91,500 | +100.0% | 1.57% | – |
| HOLX | New | Hologic, Inc. | $11,443,000 | – | 592,915 | +100.0% | 1.56% | – |
| MDVN | New | Medivation, Inc. | $10,157,000 | – | 206,439 | +100.0% | 1.38% | – |
| NBIX | New | Neurocrine Biosciences, Inc. | $9,473,000 | – | 707,990 | +100.0% | 1.29% | – |
| INCY | New | Incyte Corporation | $9,269,000 | – | 421,300 | +100.0% | 1.26% | – |
| QCOR | New | Questcor Pharmaceuticals, Inc. | $7,907,000 | – | 173,928 | +100.0% | 1.08% | – |
| AMRN | New | Amarin Corporation plcsponsored adr | $7,901,000 | – | 1,362,298 | +100.0% | 1.07% | – |
| AGN | New | Allergan, Inc. | $7,841,000 | – | 93,077 | +100.0% | 1.07% | – |
| ILMN | New | Illumina, Inc. | $7,771,000 | – | 103,841 | +100.0% | 1.06% | – |
| ALR | New | Alere, Inc. | $7,756,000 | – | 316,553 | +100.0% | 1.06% | – |
| IRWD | New | Ironwood Pharmaceuticals, Inc. | $7,642,000 | – | 768,050 | +100.0% | 1.04% | – |
| ARIA | New | ARIAD Pharmaceuticals, Inc. | $7,223,000 | – | 412,965 | +100.0% | 0.98% | – |
| IPXL | New | Impax Laboratories, Inc. | $6,876,000 | – | 344,683 | +100.0% | 0.94% | – |
| IMGN | New | Immunogen, Inc. | $6,533,000 | – | 393,773 | +100.0% | 0.89% | – |
| MCK | New | McKesson Corporation | $6,511,000 | – | 56,862 | +100.0% | 0.88% | – |
| FRX | New | Forest Laboratories, Inc. | $6,007,000 | – | 146,500 | +100.0% | 0.82% | – |
| SGNT | New | Sagent Pharmaceuticals, Inc. | $5,665,000 | – | 270,031 | +100.0% | 0.77% | – |
| ALKS | New | Alkermes plcshares | $5,589,000 | – | 194,870 | +100.0% | 0.76% | – |
| UNH | New | UnitedHealth Group, Inc. | $5,398,000 | – | 82,436 | +100.0% | 0.73% | – |
| BAX | New | Baxter International, Inc. | $5,381,000 | – | 77,675 | +100.0% | 0.73% | – |
| IDXX | New | IDEXX Laboratories, Inc. | $5,051,000 | – | 56,265 | +100.0% | 0.69% | – |
| ENDP | New | Endo Pharmaceutical Holdings, Inc. | $4,643,000 | – | 126,215 | +100.0% | 0.63% | – |
| ARAY | New | Accuray, Inc. | $4,201,000 | – | 731,943 | +100.0% | 0.57% | – |
| BMRN | New | BioMarin Pharmaceutical Inc. | $4,184,000 | – | 75,000 | +100.0% | 0.57% | – |
| CVS | New | CVS Caremark Corporation | $4,094,000 | – | 71,591 | +100.0% | 0.56% | – |
| ACOR | New | Acorda Therapeutics, Inc. | $3,724,000 | – | 112,881 | +100.0% | 0.51% | – |
| MACK | New | Merrimack Pharmaceuticals Inc. | $3,618,000 | – | 537,600 | +100.0% | 0.49% | – |
| ELN | New | Elan Corporation plcadr | $3,429,000 | – | 242,500 | +100.0% | 0.47% | – |
| IPCI | New | IntelliPharmaCeutics International, Inc. | $2,811,000 | – | 1,735,000 | +100.0% | 0.38% | – |
| RIGL | New | Rigel Pharmaceuticals, Inc. | $2,763,000 | – | 827,100 | +100.0% | 0.38% | – |
| AUXL | New | Auxilium Pharmaceuticals, Inc. | $2,121,000 | – | 127,520 | +100.0% | 0.29% | – |
| SNTA | New | Synta Pharmaceuticals Corporation | $1,880,000 | – | 376,750 | +100.0% | 0.26% | – |
| DNDNQ | New | Dendreon Corporation | $1,552,000 | – | 376,728 | +100.0% | 0.21% | – |
| CERE | New | Ceres, Inc. | $1,304,000 | – | 416,481 | +100.0% | 0.18% | – |
| OGXI | New | OncoGenex Pharmaceuticals, Inc. | $1,108,000 | – | 113,100 | +100.0% | 0.15% | – |
| MEIP | New | MEI Pharma Inc. | $1,061,000 | – | 148,820 | +100.0% | 0.14% | – |
| SUPN | New | Supernus Pharmaceuticals Inc. | $905,000 | – | 140,800 | +100.0% | 0.12% | – |
| ECYT | New | Endocyte, Inc. | $790,000 | – | 60,200 | +100.0% | 0.11% | – |
| CRTX | New | Cornerstone Therapeutics, Inc. | $529,000 | – | 66,112 | +100.0% | 0.07% | – |
| ICAD | New | iCAD, Inc. | $531,000 | – | 88,527 | +100.0% | 0.07% | – |
| GCVRZ | New | Sanofiright 12/31/2020 | $200,000 | – | 103,665 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-07-31
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.